214 related articles for article (PubMed ID: 31308291)
1. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
[TBL] [Abstract][Full Text] [Related]
2. Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines.
Ong SM; Saeki K; Tanaka Y; Nishimura R; Nakagawa T
Vet J; 2016 Dec; 218():51-59. PubMed ID: 27938709
[TBL] [Abstract][Full Text] [Related]
3. YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo.
Zhang Z; Ma L; Wang J
Oncol Rep; 2015 Aug; 34(2):1074-80. PubMed ID: 26081496
[TBL] [Abstract][Full Text] [Related]
4. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
5. Commitment toward cell death by activation of autophagy with survivin inhibitor YM155 in two canine squamous cell carcinoma cell lines with high expression of survivin.
Miyamoto R; Tani H; Ikeda T; Saima H; Tamura K; Bonkobara M
Res Vet Sci; 2021 Mar; 135():412-415. PubMed ID: 33160684
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour efficacy of etoposide alone and in combination with piroxicam against canine osteosarcoma in a xenograft model.
Ong SM; Saeki K; Kok MK; Tanaka Y; Choisunirachon N; Yoshitake R; Nishimura R; Nakagawa T
Res Vet Sci; 2017 Aug; 113():130-135. PubMed ID: 28957780
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
8. Canine squamous cell carcinoma cell lines with high expression of survivin are sensitive to survivin inhibitor YM155.
Miyamoto R; Kurita S; Tani H; Ikeda T; Ishizaka M; Saima H; Kobayashi M; Tamura K; Bonkobara M
Vet J; 2018 Oct; 240():31-36. PubMed ID: 30268330
[TBL] [Abstract][Full Text] [Related]
9. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
Zhang S; Wang X; Gu Z; Wang L
Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
[TBL] [Abstract][Full Text] [Related]
11. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.
Huang J; Lyu H; Wang J; Liu B
Cancer Lett; 2015 Oct; 366(2):160-72. PubMed ID: 26123662
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
13. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.
Wolfe TD; Pillai SP; Hildreth BE; Lanigan LG; Martin CK; Werbeck JL; Rosol TJ
Clin Exp Metastasis; 2011 Apr; 28(4):377-89. PubMed ID: 21374084
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
15. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
16. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
[TBL] [Abstract][Full Text] [Related]
17. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.
Couto JI; Bear MD; Lin J; Pennel M; Kulp SK; Kisseberth WC; London CA
BMC Vet Res; 2012 Dec; 8():244. PubMed ID: 23244668
[TBL] [Abstract][Full Text] [Related]
18. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
19. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C
Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]